Navigation Links
Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Date:5/19/2009

First Patent to be Issued from Among Intradigm's Large Collection of Pending siRNA Sequence Patents

PALO ALTO, Calif., May 19 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases." The issued patent covers a specific double-stranded siRNA sequence that is directed against the angiogenic pathway and which possesses therapeutic potential in the treatment of cancer. This is the first patent to be issued to Intradigm related to an active pharmaceutical ingredient in the RNAi space and is one of a significant number of pending patent applications worldwide covering proprietary Intradigm siRNA sequences against more than 50 clinically relevant targets.

As Intradigm's first issued piece of intellectual property (IP) related to an active pharmaceutical ingredient, this patent supplements the company's existing patent portfolio, providing Intradigm issued IP in each of the three essential areas of RNAi therapeutic development: target sequences, delivery and siRNA structural features. Based on this broad IP portfolio, Intradigm is in a uniquely strong position within the RNAi therapeutic industry, particularly among other private companies in the space.

"With the continued rapid maturation of the RNAi industry, it is critical that Intradigm properly protect the breakthroughs that are being pioneered in our labs. As we continue to take important steps to execute our strategy, we find ourselves in the enviable position of possessing one of the industry's broadest and strongest RNAi IP portfolios," said Philip Haworth, chief executive officer of Intradigm. "With today's development, we have further broadened and strengthened this position and can now claim to have a portfolio that contains issued patents in all three of our RNAi therapeutic areas of focus."

"While the issuance of this important patent is cause for excitement on its own, the broader message regarding the potential of Intradigm's siRNA sequence IP is particularly gratifying," said Mike Riley, Intradigm's vice president of intellectual property and corporate development. "Based on today's patent issuance, we have a great deal of confidence concerning the large number of pending sequence-specific patent applications currently under review worldwide. Each subsequent patent issuance related to an active pharmaceutical ingredient will only serve to further strengthen Intradigm's position of leadership in the RNAi therapeutic space."

Intradigm possesses one of the industry's strongest RNAi IP positions including key assets strategically licensed from both the University of Massachusetts Medical School and the Massachusetts Institute of Technology (MIT). The company's IP estate of issued patents and pending applications broadly covers structural features for a next generation of RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics, and proprietary siRNA sequence applications.

ABOUT INTRADIGM

Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. Intradigm is unique among private companies, with its comprehensive RNAi therapeutics platform consisting of structural features for a next generation of RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics and proprietary siRNA sequences. Our proprietary delivery technology is unique in its potential to offer safe and effective systemic administration using a library of novel peptide-based biodegradable polymers.

We have established an impressive proprietary portfolio of siRNA sequences against more than 50 highly valued oncology and other disease targets. In addition, we have secured an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences. Our goal is to grow Intradigm to become a leading company in enabling the development of novel RNAi therapeutics against a broad range of therapeutic targets using our extensive internally developed know-how and our comprehensive IP estate.

For more information on Intradigm, please visit www.intradigm.com.


'/>"/>
SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards
2. NxStage Announces Strategic Business Alliance with Asahi Kasei Kuraray Medical
3. Beckman Coulter, Inc. Announces Common Stock Offering
4. Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains
5. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
6. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
7. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
8. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
9. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
10. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
11. International Student Insurance Announces Website Redesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation ... the opening of a Greenville, South Carolina location. The lab has set ... Greenville. , “We’ve been working with South Carolina clients for years from our office ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly ... Delgado, June 9--24, 2017. This sacred and spiritual journey during the Summer ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: